Palvella Therapeutics, Inc. Capital Expenditures Incurred but Not yet Paid
Palvella Therapeutics, Inc. (PVLA) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-14.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2024-08-14
- Palvella Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-09-30 was -$74.00K, a 562.50% decline year-over-year.
- Palvella Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-06-30 was $58.00K.
- Palvella Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-03-31 was $16.00K, a 94.63% decline year-over-year.
- Palvella Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Palvella Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $193.00K, a 18.57% decline from fiscal 2021.
- Palvella Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2021 was $237.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2024-06-30 | $0.00 10-Q · filed 2024-08-14 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$74.00K derived: sum of 2 quarters · filed 2024-03-29 | -$16.00K derived: sum of 3 quarters · filed 2024-08-14 | $0.00 10-K · filed 2024-03-29 |
| 2023-09-30 | -$74.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$16.00K derived: sum of 2 quarters · filed 2024-08-14 | $0.00 10-Q · filed 2023-11-14 | $162.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-06-30 | $58.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $74.00K 10-Q · filed 2024-08-14 | $236.00K derived: sum of 3 quarters · filed 2024-08-14 | $252.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $16.00K 10-Q · filed 2023-05-11 | $178.00K derived: sum of 2 quarters · filed 2024-03-29 | $194.00K derived: sum of 3 quarters · filed 2024-03-29 | -$89.00K derived: sum of 4 quarters · filed 2024-03-29 |
| 2022-12-31 | $162.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $178.00K derived: sum of 2 quarters · filed 2024-03-29 | -$105.00K derived: sum of 3 quarters · filed 2024-03-29 | $193.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | $16.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$267.00K derived: sum of 2 quarters · filed 2023-11-14 | $31.00K 10-Q · filed 2023-11-14 | $268.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$283.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $15.00K 10-Q · filed 2023-08-10 | $252.00K derived: sum of 3 quarters · filed 2023-08-10 | |
| 2022-03-31 | $298.00K 10-Q · filed 2023-05-11 | $535.00K derived: sum of 2 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $237.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $237.00K 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |